The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis

BACKGROUND: Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that has proven efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Despite its efficacy, it has also been associated with the development of potentially serious adverse events such as t...

Descripción completa

Detalles Bibliográficos
Autores principales: Marrapodi, Maria Maddalena, Mascolo, Annamaria, di Mauro, Gabriella, Mondillo, Gianluca, Pota, Elvira, Rossi, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354602/
https://www.ncbi.nlm.nih.gov/pubmed/35935358
http://dx.doi.org/10.3389/fped.2022.929122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354602/
https://www.ncbi.nlm.nih.gov/pubmed/35935358
http://dx.doi.org/10.3389/fped.2022.929122

Ejemplares similares